Paradigm has announced they have initiated genomic testing for Pharmatech’s AccessPPM Cancer Registry.
Pharmatech’s AccessPPM is a cancer registry designed to collect EMR data and genomic information to help best match cancer patients with targeted clinical trials. The AccessPPM program and associated protocol currently includes 55 sites and is quickly poised to expand to Pharmatech’s entire research network of 345 cancer centers.
“We are truly pleased to begin providing our genomic profiling services for the patients served by AccessPPM,” noted Dr. Robert Penny, CEO of Paradigm. “Our ability to provide clinical grade sequencing through our PCDx test to physician clients in 4-5 business days ensures that continuity of care is maintained and that patients are quickly and efficiently matched to the appropriate therapies and clinical trials. “We anticipate that Pharmatech’s network of sites and cancer centers will be of strategic value to the long-term growth and expansion.”
Rob Bohacs, CEO of Pharmatech, noted, “This is a great milestone as we begin ramping the AccessPPM program. We believe AccessPPM will change the way today’s oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research.” “Our relationship with Paradigm is a logical and natural fit for this program.”
Date: August 5, 2014
SUBSCRIBE TO OUR BLOG IN THE RIGHT SIDEBAR MENU TO RECEIVE OUR DAILY BLOG POST DIRECTLY TO YOUR E-MAIL
SUBSCRIBE TO OUR NEWSLETTER TO RECEIVE A MONTHLY MAIL WITH MORE RELEVANT INDUSTRY AND COMPANY NEWS